Immunogenicity of a three-component acellular pertussis vaccine administered at birth
Immunogenicity of a three-component acellular pertussis vaccine administered at birth
复制标题
DOI：
10.1542/peds.111.5.1042
复制
发表时间：
2003-05-01
期刊：
影响因子：
8
通讯作者：
Chirico, G
中科院分区：
文献类型：
--
作者：
Belloni, C;De Silvestri, A;Chirico, G
客观的。除了在 3、5 和 11 个月时接种推荐的疫苗接种方案外，旨在评估出生后 6 个月内接种一剂疫苗的婴儿，含有丝状血凝素 (FHA)、百日咳毒素 (PRN) 和基因解毒百日咳毒素 (PT) 的三组分无细胞百日咳 (aP) 疫苗的免疫原性。此外，我们研究了母体抗体对 aP 疫苗反应的影响。方法。我们使用酶联免疫吸附测定法评估了 45 名出生时以及 3、5 和 11 个月时免疫的婴儿（组 1）以及 46 名在 3、5 和 11 个月时免疫的婴儿（组 2）的免疫球蛋白 G 抗体水平。所有母亲在分娩时也接受了测试。结果。 5 个月大时，第 1 组（接受 2 剂）的抗 PT、抗 FHA 和抗 PRN 几何平均效价显着高于第 2 组（接受 1 剂）。 6 个月时，第 1 组抗 PRN 和抗 FHA 的几何平均滴度显着高于第 2 组，而抗 PT 没有观察到显着差异。结论。出生时接种疫苗对于 6 个月以下婴儿早期预防百日咳病可能很重要，尤其是在意大利，该国建议接种 aP 疫苗的年龄为 3、5 和 11 个月。
Objective. To evaluate within the first 6 months of birth the immunogenicity of a 3-component acellular pertussis (aP) vaccine containing filamentous hemagglutinin (FHA), pertactine (PRN), and genetically detoxified pertussis toxin ( PT) in infants who received a dose of vaccine at birth, in addition to the recommended schedule administered at 3, 5, and 11 months. Furthermore, we investigated the influence of maternal antibodies on aP vaccine response.Methods. We used enzyme-linked immunosorbent assay to evaluate immunoglobulin G antibody levels in 45 infants immunized at birth and at 3, 5, and 11 months ( group 1) and in 46 infants immunized at the ages of 3, 5, and 11 months ( group 2). All mothers were also tested at delivery.Results. At the age of 5 months the geometric mean titer of anti-PT, anti-FHA, and anti-PRN was significantly greater in group 1 ( who had received 2 doses) than in group 2 ( 1 dose). At 6 months geometric mean titers were significantly higher in group 1 than in group 2 for anti-PRN and anti-FHA, whereas no significant differences were observed for anti-PT.Conclusions. Immunization at birth may be important for an earlier prevention of the pertussis disease in infants under 6 months, especially in Italy, where the recommended ages for aP vaccine administration are 3, 5, and 11 months.